Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

v3.7.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Condensed Consolidated Statements Of Operations        
Revenues
Operating expenses:        
General and administrative 163,103 111,852 294,204 202,291
Total operating expenses 163,103 111,852 294,204 202,291
Loss from operations (163,103) (111,852) (294,204) (202,291)
Other income (expense):        
Gain/(loss) on fair value adjustment - derivatives 189,113 (124,306)
Interest expense (47,320) (38,445) (92,847) (110,229)
Interest expense - beneficial conversion feature (25,000) (21,500) (6,250)
Total other income (expense) 116,793 (38,445) (238,653) (116,479)
Loss before provision for income taxes (46,310) (150,297) (532,857) (318,770)
Net loss (46,310) (150,297) (532,857) (318,770)
Less: Net loss attributable to noncontrolling interest 1,054 1,052 (233) 2,123
Net loss attributable to TranBioTec, Inc. $ (45,256) $ (149,245) $ (533,090) $ (316,647)
Net loss per share        
(Basic and fully diluted) $ 0.000 $ (0.002) $ (0.006) $ (0.005)
Weighted average number of common shares outstanding 102,285,400 67,751,068 88,320,709 66,885,683